Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that RET oncogenic variants status confers therapeutic sensitivity to Selpercatinib in patients with Medullary Thyroid Cancer.
The U.S. Food and Drug Administration granted approval to selpercatinib for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.
This statement is based on a regulatory approval from the Food and Drug Administration:
RETEVMO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.